Microglial activation in Parkinson’s disease using [18F]-FEPPA
暂无分享,去创建一个
S. Houle | A. Strafella | P. Rusjan | Y. Koshimori | Jinhee Kim | Sarah Coakeley | C. Ghadery | Madeleine Harris
[1] H. Miyajima,et al. Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study , 2016, Annals of Nuclear Medicine.
[2] Alan A. Wilson,et al. Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease , 2015, PloS one.
[3] Alan A. Wilson,et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. , 2015, JAMA psychiatry.
[4] B. Pollock,et al. In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA , 2015, Molecular Psychiatry.
[5] Alan A. Wilson,et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. , 2015, Schizophrenia bulletin.
[6] E. Rabiner,et al. Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer’s disease patients and control subjects , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[7] Alan A. Wilson,et al. Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [18F]‐FEPPA , 2014, Synapse.
[8] Alan A. Wilson,et al. Kinetic Modeling of the Monoamine Oxidase B Radioligand [11C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[9] Alan A. Wilson,et al. Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA , 2014, NeuroImage.
[10] F. Turkheimer,et al. Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. , 2013, Parkinsonism & related disorders.
[11] Paul Edison,et al. Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia , 2013, Neuropsychopharmacology.
[12] B. Lopresti,et al. Molecular imaging of microglia/macrophages in the brain , 2013, Glia.
[13] E. Katunina,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[14] D. Perani,et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. , 2013, Parkinsonism & related disorders.
[15] Alan A. Wilson,et al. Translocator Protein (18 kDa) Polymorphism (rs6971) Explains in-vivo Brain Binding Affinity of the PET Radioligand [18F]-FEPPA , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[16] V. Papadopoulos,et al. Structural and functional evolution of the translocator protein (18 kDa). , 2012, Current molecular medicine.
[17] Roger N Gunn,et al. An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] Sylvain Houle,et al. Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [18F]-FEPPA and Positron Emission Tomography , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[19] Robert B. Innis,et al. Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands , 2011, The Journal of Nuclear Medicine.
[20] A. Rehemtulla,et al. Molecular Imaging , 2009, Methods in Molecular Biology.
[21] Gerhard Rammes,et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders , 2010, Nature Reviews Drug Discovery.
[22] Roger N Gunn,et al. Two Binding Sites for [3H]PBR28 in Human Brain: Implications for TSPO PET Imaging of Neuroinflammation , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[23] K. Leenders,et al. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? , 2010, Parkinsonism & related disorders.
[24] C. Martini,et al. The spontaneous Ala147Thr amino acid substitution within the translocator protein influences pregnenolone production in lymphomonocytes of healthy individuals. , 2009, Endocrinology.
[25] S. Houle,et al. Parametric modeling of [11C]harmine acquired on the HRRT PET , 2009 .
[26] S. Galderisi,et al. Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. , 2009, Psychiatric genetics.
[27] Hervé Boutin,et al. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[28] Sylvain Houle,et al. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. , 2008, Nuclear medicine and biology.
[29] Ming-Kai Chen,et al. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. , 2008, Pharmacology & therapeutics.
[30] Shitij Kapur,et al. An automated method for the extraction of regional data from PET images , 2006, Psychiatry Research: Neuroimaging.
[31] Alexander Hammers,et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.
[32] E. Yoshikawa,et al. Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.
[33] Alexander Gerhard,et al. Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study , 2005, NeuroImage.
[34] Badreddine Bencherif,et al. Application of MRI-based partial-volume correction to the analysis of PET images of mu-opioid receptors using statistical parametric mapping. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] H. Park,et al. Effects of peripheral benzodiazepine receptor ligands on proliferation and differentiation of human mesenchymal stem cells , 2004, Journal of cellular physiology.
[36] Makoto Sawada,et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.
[37] R B Banati,et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy , 2003, Neurology.
[38] S. Galiègue,et al. Peripheral benzodiazepine receptors and mitochondrial function , 2002, Neurochemistry International.
[39] F E Turkheimer,et al. Statistical Modeling of Positron Emission Tomography Images in Wavelet Space , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[40] W. Streit,et al. Microglial Response to Brain Injury: A Brief Synopsis , 2000, Toxicologic pathology.
[41] R. Dobbs,et al. Association of circulating TNF‐α and IL‐6 with ageing and parkinsonism , 1999 .
[42] R. Dobbs,et al. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. , 1999, Acta neurologica Scandinavica.
[43] Peter Riederer,et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.
[44] P Riederer,et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.
[45] P. Riederer,et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.
[46] P. Riederer,et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. , 1994, Neuroscience letters.
[47] J. Nurnberger,et al. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. , 1991, Nucleic acids research.
[48] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[49] E. Costa,et al. The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. , 1990, The Journal of biological chemistry.
[50] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.